Vaxart Inc (VXRT) Stock: Assessing the Risk and Reward

The stock of Vaxart Inc (VXRT) has gone down by -0.75% for the week, with a -1.15% drop in the past month and a 98.83% rise in the past quarter. The volatility ratio for the week is 6.69%, and the volatility levels for the past 30 days are 7.66% for VXRT. The simple moving average for the past 20 days is 1.16% for VXRT’s stock, with a 44.90% simple moving average for the past 200 days.

Is It Worth Investing in Vaxart Inc (NASDAQ: VXRT) Right Now?

The 36-month beta value for VXRT is at 0.58. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for VXRT is 171.49M, and currently, shorts hold a 9.10% of that float. The average trading volume for VXRT on April 03, 2024 was 2.04M shares.

VXRT) stock’s latest price update

Vaxart Inc (NASDAQ: VXRT)’s stock price has gone decline by -2.35 in comparison to its previous close of 1.24, however, the company has experienced a -0.75% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-27 that SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C.

Analysts’ Opinion of VXRT

Many brokerage firms have already submitted their reports for VXRT stocks, with Jefferies repeating the rating for VXRT by listing it as a “Buy.” The predicted price for VXRT in the upcoming period, according to Jefferies is $12 based on the research report published on December 29, 2021 of the previous year 2021.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $15. The rating they have provided for VXRT stocks is “Overweight” according to the report published on November 02nd, 2021.

B. Riley Securities gave a rating of “Neutral” to VXRT, setting the target price at $9 in the report published on June 29th of the previous year.

VXRT Trading at 4.08% from the 50-Day Moving Average

After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.84% of loss for the given period.

Volatility was left at 7.66%, however, over the last 30 days, the volatility rate increased by 6.69%. Over the last 50 days, in opposition, the stock is trading +57.14% upper at present.

During the last 5 trading sessions, VXRT fell by -0.82%, which changed the moving average for the period of 200-days by +38.75% in comparison to the 20-day moving average, which settled at $1.1970. In addition, Vaxart Inc saw 111.40% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for VXRT

Current profitability levels for the company are sitting at:

  • -14.56 for the present operating margin
  • 0.2 for the gross margin

The net margin for Vaxart Inc stands at -14.41. The total capital return value is set at -1.07. Equity return is now at value -97.94, with -67.13 for asset returns.

Based on Vaxart Inc (VXRT), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -7.72. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -57.6.

Currently, EBITDA for the company is -78.85 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 35.31. The receivables turnover for the company is 1.9for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.


In conclusion, Vaxart Inc (VXRT) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts